Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters "good" macrophage behaviour within the vessel wall.

Blood vessel © SHUTTERSTOCK

Atherosclerosis is a chronic inflammatory disease and the main driver of cardiovascular diseases such as stroke and heart attack. It causes fatty substances to build up and block the arteries, restricting blood flow and oxygen supply to vital organs. Current therapies treating atherosclerosis involves lowering cholesterol and reopening blocked arteries. Recent studies have shown a third avenue of therapy, that involves counteracting inflammation by targeting white blood cells.

Macrophages (from the ancient Greek "big eater") are the most abundant white blood cell type that resides in both healthy and diseased blood vessels. On the whole, they have been mostly thought to drive inflammation and promote plaque build-up. However, macrophages are very heterogenous and little is understood about their individual role in disease.

Published in Nature Communications, this new study shows that a subset of macrophages is actually fighting against plaque build-up within the artery. CLEC4A2 is a molecule that is highly expressed by macrophages in blood vessels where it fosters protective properties of macrophages by dampening excessive inflammation and ensuring lipid handling.

Inhye Park, first author, and Novo Nordisk Postdoctoral Research Fellow at the Kennedy Institute of Rheumatology, University of Oxford said: "Using single cell biology, we identify a C-type lectin receptor called CLEC4A2 that determines the fate of monocytes in tissues, and drives the tissue adaptation of macrophages with protective properties. Cell ablation techniques showed that CLEC4A2+ macrophages limit excessive plaque build-up. CLEC4A2 instructs macrophages to gain their identity of resident vascular macrophages and their protective qualities that they use to fend off atherosclerosis within the artery. CLEC4A2 not only guides monocyte differentiation into a protective macrophage state but also maintains homeostatic properties in macrophages."

"Our findings challenge the widely held belief that macrophages only play a harmful role in cardiovascular disease, with the discovery that we have a powerful ally within the vessel wall itself that can protect our arteries from the build-up of fatty deposit," said Claudia Monaco, corresponding author and Professor of Cardiovascular Inflammation at the Kennedy Institute. "Understanding how we can exploit this new pathway for making new therapies is a breakthrough to combat atherosclerosis by making the patients' own immune system work for them rather than against them."

The study was funded by the Kennedy Trust for Rheumatology Research, the European Commission and the Novo Nordisk Foundation.

Similar stories

Fat tissues can play a protective role against inflammation in the intestine

A new study in The EMBO Journal has revealed how fat tissues might provide a protective role in intestinal inflammation opening new lines of research into the treatment of inflammatory bowel diseases.

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.